Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 12/20 | 0.77 |
| ▸ | BACE1 | P56817 | 2/20 | 0.54 |
| ▸ | CDC7 | O00311 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149619 | 0.87 | XDH (1.00) | XDHBACE1 | |
| SCHEMBL2403432 | 0.79 | XDH (1.00) | XDHBACE1 | |
| SCHEMBL4146196 | 0.77 | XDH (0.65) | XDHBACE1 | |
| SCHEMBL1823306 | 0.77 | PRKDC (0.58) | XDHCDC7 | |
| SCHEMBL4142212 | 0.77 | BACE1 (0.76) | XDHBACE1MAOBL3MBTL1 | |
| SCHEMBL28514471 | 0.76 | ACHE (0.60) | XDHBACE1CDC7MAOB | |
| SCHEMBL8598725 | 0.75 | ALDH1A1 (0.55) | BACE1MAOB | |
| SCHEMBL9905389 | 0.75 | PIK3CD (0.56) | XDHBACE1CDC7MAOB | |
| Bromide SCHEMBL8359230 | 0.74 | ALDH1A1 (0.55) | BACE1MAOB | |
| SCHEMBL379281 | 0.74 | MAOB (0.67) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| CN-101084198-A | Substituted amino-pyrimidones and uses thereof | ASTRAZENECA AB (SE) | 2007-12-05 | — | — | CN | disclosed |
| CN-101084199-A | Substituted amino-compounds and uses thereof | ASTRAZENECA AB (SE) | 2007-12-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | APP, PSEN1, BACE1 | XDH 951/4885BACE1 3/4885CDC7 3735/4885 |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | APP, PSEN1, PSEN2 | XDH 259/4885BACE1 4/4885CDC7 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.